Added to YB: 2026-02-18
Pitch date: 2026-02-14
CPH.TO [neutral]
Cipher Pharmaceuticals Inc.
+31.39%
current return
Author Info
Petty Cash shares microcap investing ideas (mainly in Canada) in their newsletter. Sign up for the newsletter.
Company Info
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
Market Cap
CAD 330.8M
Pitch Price
CAD 14.56
Price Target
N/A
Dividend
N/A
EV/EBITDA
13.65
P/E
12.45
EV/Sales
6.52
Sector
Pharmaceuticals
Category
growth
CPH Update
CPH.TO (update): Canadian pharma w/ Epuris, Absorica, Natroba (head lice). Post-ParaPRO acquisition transforming business. Est. steady-state ~$55M rev, $25-30M EBITDA. Natroba expansion (Canada approval pending, US growth, global out-licensing potential), Absorica in-house 2027 (Sun arbitration ongoing). Trading ~10x EV/EBITDA vs potential upside from market share gains, geographic expansion, optionality on MOB-015 nail fungus, CF-101 psoriasis. Risks: Natroba stalls, Absorica transition, arbitration loss.
Read full article (7 min)